Search

DNA analysis is becoming an important diagnostic and prognostic adjunct test in urinary cytology. The aim of this study was to compare the results of DNA flow cytometry (FCM) with the cytologic diagnosis of bladder washings (BW). DNA ploidy was evaluated in 251 BW. In 65 cases, follow-up surgical biopsies were available. Cytology results were classified as positive and negative, and FCM results were categorized as diploid and aneuploid. Both tests were evaluated independently. Cases were defined as discordant if the cytology was negative and FCM was aneuploid, or if the cytology was positive and FCM was diploid. All discordant cases were reviewed, and positive predictive values (PPV) for FCM and cytology were calculated for cases with follow-up biopsy results. Cytologic evaluation classified 181 cases as negative, with 175 of them diploid and 6 aneuploid; and 70 as positive, with 53 of them diploid and 17 aneuploid. Overall, there were 59 discordant cases (23.5%, with a confidence limit of 18.2-28.8%). Of 6 aneuploid/cytology-negative cases, biopsies were available in 4 cases and showed one grade 1, two grade 2, and one grade 3 urothelial carcinoma (UC). Reanalysis of these 6 cytology specimens showed 1 case that should have been interpreted as positive (false negative), 4 true negatives, and 1 polyoma virus infection. Out of 53 diploid/cytology-positive cases, biopsies were available in 45 cases and showed nine grade 1, 14 grade 2, three grade 3 UCs, 11 UCs in situ, and eight negative biopsies. The PPV for cytology was 85%, and the PPV for FCM was 95%. We concluded that FCM, which requires a large number of cells, often cannot detect small aneuploid populations, which are present particularly in cases of UC in situ., (Copyright 2000 Wiley-Liss, Inc.)

DNA ploidy determinations have been shown to have clinical application in predicting disease progression, survival, or response to anti-androgen therapies in prostate carcinomas. Since intra-tumor heterogeneity may have a profound effect on DNA measurements, we determined the frequency of DNA ploidy and proliferation (here S-phase fraction) heterogeneity in early prostatic carcinomas, and estimated the potential impact of heterogeneity on predicting disease course, survival, or response to therapy. Using image and flow cytometric analysis of archival, paraffin-embedded prostate tumors, we measured DNA ploidy in individual foci of prostatic carcinoma in stage T1a, T1b and T1c disease. Image analysis studies included the use of Feulgen stained tissue sections, and a comparison of these results with flow cytometric DNA ploidy determinations on nuclei isolated from the same tumor foci. Flow cytometry was also used to measure DNA Index and tumor S-phase fraction, in some cases using multiparameter analysis of isolated nuclei to determine DNA content and the level of the proliferation-associated antigen, p105. Our results indicate that DNA aneuploid foci of prostate carcinoma are infrequently seen in stage T1a disease (13% of the individuals studied), and that the presence of both DNA diploid and aneuploid foci in the same sample is seen in less than 10% of these individuals. Stage T1b and T1c tumors containing only DNA diploid nuclei are seen, though these are likely most common in low volume, low Gleason grade tumors. By using flow cytometry to compare these results with those using image analysis of the same tumor foci, we demonstrated that the majority (> 75%) of these aneuploid tumors are DNA tetraploid. Our data on prostate tumor S-phase fractions indicate that DNA diploid tumors generally have a lower S-phase than DNA aneuploid foci (including comparisons of DNA diploid and aneuploid foci in the same prostate tumor). These results support the model that early prostate tumors are DNA diploid and have a low S-phase, and that these tumors likely evolve to DNA tetraploid tumors with a similar low S-phase fraction.

Clear cell adenocarcinoma in a urethral diverticulum in the female is a very rare and unusual tumor. We recently treated two patients with this tumor. Their presentation, histologic evaluation, and management are reviewed in light of the limited experience in the literature.

Definitive treatment of localized carcinoma of the prostate has included radical surgery, external beam radiation therapy, and interstitial radiation therapy. The interstitial agent most commonly used is Iodine-125. Forty-eight patients were treated with interstitial radiation therapy using Iodine-125 implants with a median follow-up of 55 months. Forty-three percent of the evaluable patients had progressive disease with approximately 50% progressing at 5 years by Kaplan-Meier analysis. Overall actuarial survival in the group was 80% at 5 years. This and several other studies suggest that control of prostate cancer with Iodine-125 seeds may be suboptimal as compared with other treatment modalities, especially the radical retropubic prostatectomy. Analysis of treatment parameters is presented along with a discussion of the current status and future prospects for treatment of localized carcinoma of the prostate with interstitial radiation therapy.

The analysis of data generated on a flow cytometer (FCM) is often performed on a computer obtained especially for dedicated use with the flow cytometer. This computer component can be expensive and also presents the FCM user with the added burden of mastering specialized programming language or of accepting the secret analytical processes of protected proprietary program routines. We believe that the evolution of more accurate and efficient FCM analyses that have the power to consider complex signal distributions can be assisted by the availability of analysis programs written in languages common to many users. DNA analysis routines written for a relatively inexpensive microcomputer (IBM PC/XT) in Basic and Pascal are described here. The routines can automatically process multiple FCM data files and can provide high-resolution graphic hardcopy. A foreground/background utilization is also described that allows the computer to be available for other uses in the laboratory.